Loading
OT
Omega Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Feb 2023.
Omega Therapeutics, Inc.: what insiders have been doing
Headquartered in Cambridge, United States, Omega Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Omega Therapeutics, Inc. has published a filing in the past twelve months. The most recent one dates from 5 June 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Cambridge, United States
Source: Wikidata (CC0).
Insider Decl.
13
Thresholds
n/a
Buy Volume
€13M
4 ops. · all time
Sell Volume
€414,837
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$124k
Net income-US$83.9M-67658.3% margin
Last declaration on 5 June 2023
Declarations13 total
5,000 shares@ US$8.009.0% of flowCommon StockSEC:0000899243-23-014449:0
5,000 shares@ US$8.008.8% of flowCommon StockSEC:0000899243-23-012077:0
5,000 shares@ US$8.008.8% of flowCommon StockSEC:0000899243-23-011034:0
10,000 shares@ US$8.0018.2% of flowCommon StockSEC:0000899243-23-009094:0
1,993,986 shares@ US$5.78100.0% of flowCommon StockSEC:0000899243-23-006241:0
Canonical exit: 28 May 2023 (T+90)
20,000 shares@ US$8.0035.9% of flowCommon StockSEC:0000899243-23-001594:0
10,000 shares@ US$8.0019.3% of flowCommon StockSEC:0000899243-22-031138:0
11,300 shares@ US$0.53100.0% of flowCommon StockSEC:0000899243-22-004562:0
1,088,470 sharesCommon StockSEC:0000899243-21-031797:0
1,088,470 sharesCommon StockSEC:0000899243-21-031796:0
53,082 shares@ US$17.00100.0% of flowCommon StockSEC:0000899243-21-031303:0
Canonical exit: 1 Nov 2021 (T+90)
75,000 shares@ US$16.1379100.0% of flowCommon StockSEC:0000899243-21-031304:0
Canonical exit: 28 Oct 2021 (T+90)
2,941 shares@ US$17.00100.0% of flowCommon StockSEC:0000899243-21-031305:0
Canonical exit: 1 Nov 2021 (T+90)
13 of 13 declarations
About Omega Therapeutics, Inc.
Omega Therapeutics, Inc. (ticker: OMGA) is a U.S.-listed biotechnology company trading on the Nasdaq market in the United States. Its headquarters are in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the country. Founded in 2017 by Flagship Pioneering, Omega was built around a differentiated scientific thesis: programmable epigenetic medicines delivered through mRNA, with the goal of modulating gene expression at the pre-transcriptional level rather than simply inhibiting downstream proteins. The company’s proprietary OMEGA platform is designed to identify epigenomic targets and engineer modular “epigenomic controllers” to tune gene activity with precision.
Operationally, Omega remains a clinical-stage company. It has not commercialized any products and has not generated revenue from product sales. Its pipeline has been described as spanning oncology, multigenic diseases, immunology, regenerative medicine, and select monogenic disorders, although the company has also increasingly emphasized narrower prioritization of resources. One of its key disclosed development milestones is OTX-2002, a product candidate that was cleared by the U.S. Food and Drug Administration to move into clinical development. That regulatory step is important because it indicates that the platform has progressed beyond purely discovery-stage work and into human testing.
Read moreShow less
From a competitive standpoint, Omega operates in a highly innovative but high-risk segment of biotechnology. The investment case is primarily driven by scientific differentiation, intellectual property strength, clinical execution, and access to capital. If the platform works as intended, the company could offer a new way to control disease biology by targeting gene regulation earlier in the causal chain. However, the company also faces the usual biotech headwinds: clinical uncertainty, regulatory risk, long development timelines, and recurring cash burn. Recent SEC filings show significant net losses since inception, underscoring the need for ongoing financing.
Recent company developments have included a strategic prioritization initiative announced in 2024 to concentrate resources on nearer-term milestones and support long-term shareholder value. Omega also disclosed a research collaboration with Novo Nordisk focused on obesity, signaling potential expansion into cardiometabolic disease beyond its earlier oncology-heavy framing. For investors in French-speaking markets, OMGA should be viewed as a speculative Nasdaq-listed biotech name with meaningful upside if the platform is validated clinically, but also with substantial execution and financing risk. Insider activity reported through SEC Form 4 filings should therefore be interpreted in the context of a development-stage company whose valuation depends heavily on clinical readouts, partnerships, and capital markets access.
